Resona Asset Management Co. Ltd. Has $4.85 Million Stock Holdings in Illumina, Inc. $ILMN

Resona Asset Management Co. Ltd. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 50,851 shares of the life sciences company’s stock after buying an additional 3,309 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Illumina were worth $4,848,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Next Capital Management LLC bought a new position in shares of Illumina in the second quarter valued at approximately $341,000. Bourgeon Capital Management LLC grew its stake in Illumina by 76.4% in the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock valued at $13,538,000 after buying an additional 61,468 shares during the last quarter. GC Wealth Management RIA LLC bought a new position in Illumina in the 2nd quarter worth $2,289,000. waypoint wealth counsel bought a new position in Illumina in the 2nd quarter worth $321,000. Finally, Allegiance Financial Group Advisory Services LLC acquired a new position in Illumina during the 2nd quarter worth $344,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction dated Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.60% of the company’s stock.

Illumina Price Performance

Shares of ILMN stock opened at $121.90 on Monday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $154.43. The company has a market capitalization of $18.63 billion, a P/E ratio of 15.43, a P/E/G ratio of 2.34 and a beta of 1.42. The stock has a 50 day moving average of $100.51 and a two-hundred day moving average of $94.57. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina’s revenue was up .4% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday. Evercore ISI raised their price objective on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Finally, UBS Group boosted their target price on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.